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Abstract 
Background: Sigma (σ) receptors are membrane‑bound proteins characterised by an unusual promiscuous ability to 
bind a wide variety of drugs and their high affinity for typical neuroleptic drugs, such as haloperidol, and their poten‑
tial as alternative targets for antipsychotic agents. Sigma receptors display diverse biological activities and represent 
potential fruitful targets for therapeutic development in combating many human diseases. Therefore, they present 
an interesting avenue for further exploration. It was our goal to evaluate the potential of ring opened spipethiane (1) 
analogues as functional ligands (agonists) for σ receptors by chemical modification.
Results: Chemical modification of the core structure of the lead compound, (1), by replacement of the sulphur atom 
with a carbonyl group, hydroxyl group and 3‑bromobenzylamine with the simultaneous presence of 4‑fluorobenzoyl 
replacing the spirofusion afforded novel potent sigma‑1 receptor ligands 7a–f, 8a–f and 9d–e. The sigma‑1 receptor 
affinities of 7e, 8a and 8f were slightly lower than that of 1 and their selectivities for this receptor two to threefold 
greater than that of 1.
Conclusions: It was found that these compounds have higher selectivities for sigma‑1 receptors compared to 
1. Quantitatitive structure–activity relationship studies revealed that sigma‑1 binding is driven by hydrophobic 
interactions.
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Background
Sigma (σ) receptors are membrane-bound proteins 
that bind several psychotropic drugs with high affinity 
[1]. They were initially proposed to be related to opi-
oid receptors [2] but were later found to be a distinct 
pharmacological entity distinguished by an unusual pro-
miscuous ability to bind a wide variety of drugs [3]. Ini-
tial interest in σ receptors came mainly from their high 
affinity for typical neuroleptic drugs, such as haloperidol, 
and their potential as alternative targets for antipsychotic 
agents [4, 5]. However, no endogenous functional ligand 
(agonist) for σ receptors has been conclusively identified.
These receptors are classified into two subtypes: sub-
type 1 (σ1 receptor) and subtype 2 (σ2 receptor) which 
are differentiated by their pharmacological profiles, dis-
tribution in tissues, functions, and molecular sizes [6], 
with the σ1 being the most documented. Basically, the 
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σ1 receptor is believed to have a ligand binding profile 
such that (+)-benzomorphans are at least fivefold to ten-
fold more potent than their corresponding (−)-isomers 
[7]. On the other hand, for the σ2 subtype, the (−)-ben-
zomorphans are more potent than their corresponding 
(+)-isomers in the binding assay. The gene coding the 
σ1 receptor has been isolated and cloned from guinea 
pig [8], mouse [9], rat [10], and human [11]. The protein 
coded by the σ1 receptor gene in rat brain consists of a 
223 amino acid sequence (23  kDa). In contrast, the σ2 
receptor has not been cloned yet and is estimated to have 
a molecular weight of 19–21.5 kDa [12]. The presence of 
a σ3 subtype has not been confirmed yet, even though its 
existence was proposed in a few papers [13–15].
The specific participation and character of σ receptors 
in the processes of the psychiatric and neurological dis-
orders is still not clear [16]. Nevertheless, some of the 
ligands have drawn attention as potentially useful antip-
sychotics, antidepressants [17, 18], anxiolytics [19], anti-
amnesics, for mental improvement [20], analgesics [21], 
anti-epileptics, anticonvulsants, and as seizure reducing 
neuroprotective agents [22]. Apart from their involvement 
in psychiatric disorders and nervous system diseases, σ 
receptors and their ligands offer a plethora of means for 
dealing with several cancer cell types through a variety of 
strategies [23]. A typical endogenous σ1 receptor regula-
tor is the hallucinogen N,N-dimethyltryptamine [24]. 
Moreover, σ1 receptor ligands have recently been shown 
to be potent noncompetitive antagonists at the N-methyl-
d-aspartate (NMDA) receptor with IC50 values similar to 
those of the dissociative anesthetic (S)-(+)-ketamine [25]. 
Ghandi et  al. recently carried out a one pot synthesis of 
new spirocyclic-2,6-diketopiperazine derivatives, with 
benzylpiperidine and cycloalkane moieties, some of which 
showed up to a 95-fold σ1/σ2 selectivity ratio [26].
Over the years, a large number of compounds with 
unrelated chemical structures have been reported to dis-
play affinity for σ receptors (Fig. 1). To explain the bind-
ing of these structurally diverse compounds to sigma 
receptors, a number of models or pharmacophores have 
been proposed [13, 27–33]. Generally, the pharmacoph-
ore (ph4) for σ1 receptor binding consists of three major 
sites: an amine site as an essential proton acceptor site, 
flanked by two hydrophobic domains, a primary hydro-
phobic site that binds phenyl group “B” from the central 
amine and a secondary binding site that binds phenyl 
group “A” from the central amine (Fig. 2). Gund and cow-


























Fig. 1 Some sigma receptor ligands
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site and aromatic rings need not be simple alkyl chains. 
They could bear a polar substituent such as S or O, which 
could be considered as the second binding site (Fig.  3). 
Other functional groups can be piperidyl, guanidinyl, 
pyrrolidyl, piperazyl, thiochromanyl, and benzamidyl [7]. 
A pharmacophore for σ2 binding has also been proposed 
[24, 30–33]. The latter is also characterized by a central 
amine site flanked by two hydrophobic sites. However, 
the two models (σ1 and σ2) differ in a number of respects, 
such as the distance between the central amine site and 
the hydrophobic sites [13, 32].  
Owing to the apparent involvement of σ receptors in a 
variety of biological processes, and the potential applica-
tions of σ ligands in pharmacology and medicine, interest 
in these receptors and their ligands has remained high, 
and there is a continuing search for new selective ligands 
that can serve either as agonists or antagonists at those 
biological processes that are mediated by σ receptors.
Among the compounds reported to bind σ receptors, 
a large number of benzylpiperidine and benzylpipera-
zine derivatives display remarkable affinity. In review-
ing these collections of compounds, our attention was 
attracted to spipethiane (1), a spirocyclic compound that 
contains the elements of benzylpiperidine. Spipethiane is 
a very potent and selective ligand for σ1 receptors (Ki: σ1, 
0.5 nM; σ2, 416 nM) [34]. The design of this compound 
was inspired by the reported high affinity of the spirote-
tralins (2) for σ1 receptors. In contrast to the spirotetra-
lins, spipethiane does not display high affinity for 5-HT2 
receptors. Consequently, the compound was one of the 
most selective σ1 ligands reported at the time. Since this 
initial discovery, the work on this spirocyclic skeleton 
has been extended to include several compounds which 
are reported to display high affinity and selectivity for σ1 
receptors, and potential antitumor activity [33, 35]. Spi-
pethiane and it analogues therefore provide interesting 
targets for further investigation.
Deprived of conformational freedom, spirocyclic com-
pounds such as spipethiane and the spirotetralins may 
derive their receptor selectivity from their ability to 
adopt only a restricted number of molecular conforma-
tions. The current study sought to investigate the role of 
spirofusion in the biological activity of the spipethiane/
spirotetralin skeleton. The compounds obtained from the 
study were tested for binding to σ1 and σ2 receptors.
Results and discussion
Compounds 7a–f, 8a–f and 9d–e were synthesized 
according to methods A–C reported in Scheme 1. Reac-
tion of 4-(4-fluorobenzoyl)piperidine with various substi-
tuted benzyl halides in the presence of sodium acetate, in 
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Fig. 3 Design of 1,4‑disubstituted piperidines from proposed pharmacophore model for sigma receptor ligands
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[36] (Scheme 1, method A). Reduction of the methanone 
analogues with LiBH4 in THF provided the correspond-
ing alcohols 8a–f [33] (Scheme 1, method B). Reductive 
amination of the methanone analogues 7d and 7e with 
3-bromobenzylamine afforded 9d and 9e (Scheme  1, 
method C) [37]. The synthesized 1,4-disubstituted piperi-
dine derivatives were evaluated for their affinity at both 
σ1 and σ2 receptors.
Sigma receptor binding
Overall, the majority of target compounds displayed 
significantly higher affinity for σ1 receptors than for σ2 
receptors (Tables 1, 2, 3). Ki values at σ1 receptors were 
below 15  nM for all the compounds except 7b, 7d, 8b 
and 8d. In contrast, all compounds except 7a and 7f 
were found to have Ki values greater than 500 nM at the 
σ2 receptor. Among the ketones, 7e and 7a emerged as 
the most potent σ1 receptor ligands followed closely by 
7c and 7f. All four compounds are para substituted, sug-
gesting that this substitution pattern is favored. In con-
trast, substitution at the ortho or disubstituted at meta 
and para positions was disfavoured, as both the 2″-nitro 
compound (7d) and 3″, 4″-dichloro substituted analogue 
(7b) displayed equally poor affinity for the σ1 recep-
tor. Reduction of the carbonyl compounds to the cor-
responding alcohols led to a significant increase in σ1 
receptor affinity for the most potent ligands: 11-fold for 
7f versus 8f; twofold for both 7a versus 8a and 7c ver-
sus 8c. In contrast, for compounds 7e versus 8e the σ1 
binding affinity decreased fivefold upon reduction of 
the carbonyl to the corresponding alcohol. Compounds 
7e, 8a and 8f exhibited the highest selectivity (ki-σ2/
σ1  =  610, 606 and 589 respectively) for σ1 receptors 
among all compounds tested, with Ki values between 1.00 
to 2.00  nM and  >500  nM for σ2 receptors; their affini-
ties were slightly lower than that of spipethiane (Ki: σ1, 
0.50  nM; σ2, 416  nM; ki-σ2/σ1  =  208) [34] but greater 
than that of (+)-pentazocine (Ki: σ1, 3.58 ± 0.20 nM; σ2, 
1923  nM; ki-σ2/σ1  =  540) [38]. Therefore, these com-
pounds are more selective than spipethiane. Compounds 
7b, 7d, 8b, 8d and 9d interact non-selectively with both 











































































7a/8a        4-F
7b/8b        3,4-Cl2
7c/8c        4-Cl
7d/8d/9d  2-NO2
7e/8e/9e  4-Br
7f/8f         4-Me
Scheme 1 Reagents: a Substituted benzyl halide, EtOH, H2O, NaOAc reflux; b LiBH4, THF, reflux; c 3‑bromobenzylamine hydrochloride, LiBH4, THF, 
HOAc, reflux
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(Ki: σ2/σ1 = 2). In particular, ortho substitution with the 
nitro group results in mediocre binding affinity for both 
receptor subtypes (σ1: 7d vs 8d vs 9d; σ2: 7d, 8d and 9d), 
2″-N). As a result, the nitro substituted analogues were 
found to be the least σ1/σ2 receptor selective ligands (Ki: 
σ2/σ1 = 2). We conclude that replacement of the spirofu-
sion in spipethiane with a hydroxymethylene or carbonyl 
group preserves affinity and selectivity for σ1 receptors.
SAR and QSAR study
Gund et al. have reported the molecular modeling of sev-
eral σ1 receptor specific ligands: PD144418, spipethiane, 
haloperidol and pentazocine in a bid to develop a ph4 for 
σ1 receptor-ligand binding under the assumption that all 
the compounds interact at the same receptor site [13]. The 
primary ph4 for the σ binding sites was defined by map-
ping the topographic arrangements of the phenyl ring, the 
N-atom, and N lone pair vector; a point was placed 2.8 Å 
tetrahedrally from N atoms to represent an interaction 
between a protonated N atom and its binding site; dummy 
atoms were built 3.5 Å above and below a phenyl ring to 
represent hydrophobic binding to a receptor. The distance 
from the C-center to the N atom was 7.14 Å, while that 
from O and C-center was 3.68 Å and from O to N atom 
was 4.17 Å. The choice of ligands used in the study was 
based on their potency, selectivity and structural diversity 
with their affinity ranging from 0.08 to 5.8 nM.
Correlation of binding affinity to σ1 receptor and van der 
Waals surface areas, dipole moments and water accessible 
surface areas of target compounds
Table 4 shows the computed values for 3D van der Waals 
surface areas (SvdW), the 2D van der Waals surface areas 
(AvdW), the AM1 dipole moments (μD(AM1)), the densities 
(d) and 3D water accessible surface areas (Swat), as well as 
the experimentally derived binding affinities (ΔGexp) and 
the predicted binding affinities (ΔGpred) obtained from the 
most significant derived QSAR equation. The three most 
significant QSAR Eqs. (1) to (3), were derived for 14 mol-
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R
2
= 0.77,RMSE = 0.51, F = 11.2
Table 1 Binding affinity of methanone analogues
a Data available from Ref. [24]
b Data available from Ref. [24]
Compound R σ1 (Ki nM) σ2 (Ki nM) Selectivity ratio 
(Ki σ2/σ1)
7a 4″‑F 2.96 ± 0.5 221.64 ± 8.0 75
7b 3″,4″‑Cl2 >434 >854 2
7c 4″‑Cl 5.98 ± 0.41 554.03 ± 34.22 93
7d 2″‑NO2 >434 >854 2
7e 4″‑Br 1.40 ± 0.5 >854 610
7f 4″‑Me 11.58 ± 0.26 151.47 ± 7.79 13
Spipethianea 0.50 416 208
(+)‑pentazozcineb 3.58 1932 540





Compound R σ1 (Ki nM) σ2 (Ki nM) Selectivity ratio 
(Ki σ2/σ1)
8a 4″‑F 1.41 ± 0.22 >854 606
8b 3″,4″‑Cl2 >434 >854 2
8c 4″‑Cl 2.49 ± 0.24 >854 343
8d 2″‑NO2 526.53 ± 69 >854 2
8e 4″‑Br 5.22 ± 0.3 >854 164
8f 4″‑Me 1.45 ± 0.4 >854 589






Compound R σ1 (Ki nM) σ2 (Ki nM) Selectivity ratio (Ki 
σ2/σ1)
9d 2″‑NO2 >434 >854 2
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where RMSE is the root mean square error and F is the 
Fischer statistic level of significance. It was observed that 
there was more than 50  % correlation with the different 
descriptors combined. This implies that there is a rela-
tionship between the σ1 receptor binding affinity of the 
target compounds and the selected parameters for the 
study. Multilinear regression analysis showed that the 
three dimensional hydrophobic (SvdW) and solvent acces-
sible surface (Swat) parameters are important factors in the 
binding affinity of the 1,4-disubstituted piperidine ana-
logues towards the σ1 receptor, because they have positive 
coefficients compared to densities and dipole moments. 
The influence of hydrophobic constants confirms the 
presence of a hydrophobic binding site at the σ1 receptor. 
The respective R2 values of 0.71, 0.74 and 0.77 indicate 
that we can account for about 70–80 % of the variability 
in binding affinity and the remaining 20–30 % of the vari-
ability in affinity cannot be accounted for by the use of the 
two to four parameters.
The correlation plots for QSAR Eqs.  (1), (2) and (3) 
have been respectively shown in Fig. 4a–c. Interestingly, 
these plots showed similarity wherein points are grouped 
into two clusters. The clusters are formed such that the 
least potent σ1 ligands (characterized by substitution at 
the ortho and meta positions) are at the bottom left while 
the most potent ligands (characterized by substitution at 
the para position) are at the top right. Thus, the QSAR 
equations are able to discriminate between the active and 
inactive σ1 binders.
Molecular electrostatic potential maps
Further structure–activity evaluation was performed by 
studying the electronic distribution of analogues through 
the use of molecular electrostatic potentials (MEPs). 
Electrostatic potential is the energy of interaction of a 
positive charge with the nuclei and electrons of a mole-
cule. The MEP surfaces are color coded, with light brown 
indicating the hydrophobic regions, red the acceptor 
regions and blue, the donor regions (availability of lone 
pairs of electrons). The MEPs will be subsequently dis-
cussed for spipethiane (cyan carbons), the most potent 
ligand (purple carbons) (7e) and the least potent ligand 
(green carbons) (8d) for the σ1 binding affinity. These are 
illustrated in Fig. 5.
The main difference between the MEPs of spipethi-
ane, the most potent and least potent ligands is observed 
around the secondary hydrophobic site (Ar1 region) 
where there is an additional field generated around 
the substituent of the pendant phenyl ring of the least 
potent ligand. This could be probably due to the fact 
that the nitro-group on the pendant phenyl group of the 
least potent ligand is strongly electron withdrawing and 
ortho substituted thereby pulling the electrons from the 
pendant phenyl group onto itself and as a result deacti-
vating the ring.
MEP maps generated for the most potent ligand (7e) 
and its corresponding alcohol (8e) show no significant 
difference (Fig.  5c), in agreement with the observation 
that both ligands are potent σ1 receptor binders. There-
fore, the difference between the most potent and least 
potent ligands lies in the type of substituent and posi-
tion of substitution on the pendant phenyl group. The 
superposition of spipethiane (cyan), the most potent 
(purple) and least potent (green) σ1 receptor ligands is 
shown in Fig. 6. A difference observed when spipethiane 
(cyan) and the most potent σ1 ligand (purple) are super-
imposed is at the Ar2 portion (the primary hydrophobic 
site). Although the superposition around this site is not 
perfect, both ligands remain potent binders to the σ1 
receptor, with high affinity and selectivity. This is possi-
ble because phamacophore studies for σ1 receptor bind-
ing have shown that this site is associated with much bulk 
tolerance [13].
Molecular surfaces of ligands
The molecular surfaces of 1,4-disubstituted piperidine 
analogues were studied to further evaluate the struc-
ture–activity relationships. Molecular surface maps pro-
vide an efficient way of comparing molecular shape and 
property. They are color coded, with blue indicating the 
mildly polar regions, green indicating the hydrophobic 
regions and purple indicating the H-bonding regions. 
Discussion on the MEPs will be for spipethiane, the most 
potent (7e) and the least potent σ1 ligand (8d), illus-
trated in Fig. 7.
The molecular shape of the geometry optimized spi-
pethiane structure is different from those of the most 
potent and least potent ligands in that, the former is lin-
ear while the latter are curved. However, the direction 
of the curvature is not identical for geometry optimized 
structures of the two compounds. Interestingly, there 
is some consistency in the hydrophobic regions of spi-
pethiane and the most potent ligand (Fig. 7a), compared 
to the least potent ligand and spipethiane (Fig. 7b). The 
molecular surface of the least potent ligand is character-
ized mostly by the mild polar and H-bond regions instead 
of the hydrophobic regions as seen for spipethiane and 
the most potent ligand. Therefore, we can conclude that 
molecular shape has minimal influence on affinity for this 
series of compounds since the most potent ligand is dif-
ferent from spipethiane in shape but similar to the least 
potent ligand.
Pharmacophore study
In this study, a comparison between the ph4 features 
generated for the target compounds with the existing 
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ph4 model for σ1 receptor ligands by Gund et  al. [13] 
was carried out. Gund et al. had proposed that, the dis-
tance from the centroid of the primary hydrophobic site 
to the N atom was 7.14 Å; from the secondary binding 
site to centroid of the primary hydrophobic site was 
3.68 Å and from the secondary binding site to N atom 
was 4.17  Å. In our model (Fig.  8), the centroids of the 
primary and secondary hydrophobic sites were chosen 
from the phenyl groups Ar2 and Ar1, respectively, and 
the following dimensions were obtained: the distance 
from the centroid to N atom is 6.30  Å for the most 
potent ligand and 6.02 Å for the least potent ligand. The 
distance from O to centroid of the most potent ligand is 
3.71 Å and that of the least potent ligand is 3.68 Å; Dis-
tance from O to N atom for most potent ligand is 4.97 Å 
and that for the least potent ligand is 5.06  Å. There-
fore, it could be concluded that the distance from the 
centroid of the primary hydrophobic site to the N atom 
may vary between 6.30 and 7.14  Å; between 3.68 and 
3.71 Å from the secondary binding site to the centroid 
of the primary hydrophobic site and between 4.17 and 
4.97 Å from O to N atom.
Experimental section
Chemistry
The reactions described below were carried out with 
commercially available chemicals, of reagent grade, that 
were used without further purification. Reagents were 
purchased from Sigma-Aldrich Chemical Company, St. 
Louis, MO, USA. The silica gel (63–200 mesh) which was 
used as the stationary phase in column chromatography 
was obtained from Mallinckrodt Baker, Inc. Phillipsburg, 
New Jersey, USA and Melting points were determined on 
a Melt—temp II Laboratory device and are uncorrected. 
All the 1,4-disubstituted piperidine derivatives were con-
verted to their HCl salts by treatment of the correspond-
ing free base with methanolic HCl. Only the HCl salts 
were submitted for pharmacological evaluation [39–46]. 
1H and 13C NMR spectra were recorded using VARIAN 
400  MHz spectrometer (1H NMR at 399.75  MHz and 
13C NMR at 100.53 MHz). Chemical shifts are presented 
in units of ppm relative to the solvent (1H NMR peak: 
7.26 ppm for CDCl3, 3.3 ppm for CD3OD, and 13C NMR 
peak: 49.1  ppm for CD3OD and 77.2  ppm for CDCl3). 
Peak multiplicities and characteristics are represented 
Table 4 Computed molecular descriptors, experimental and  theoretically obtained binding affinities for  σ1 receptor 
(obtained with the best model, Eq. 3)
These are the structures of the compounds with the assigned positions. Preferable to be inserted in the scheme
Compd d SvdW Swat AvdW μD(AM1) ΔG
exp ΔGpred ΔGres
7a 1.03 328.65 550.09 304.36 1.55 −0.47 −1.02 0.55
7b 1.01 356.64 591.24 335.12 2.16 −2.64 −1.95 −0.69
7c 1.05 343.45 565.21 317.53 1.69 −0.78 −1.16 0.38
7d 1.07 347.51 564.98 328.09 6.67 −2.64 −2.78 0.14
7e 1.14 354.30 588.50 329.31 1.58 −0.15 −1.19 1.04
7f 0.97 345.98 575.78 317.19 3.13 −1.06 −0.33 −0.73
8a 1.03 341.05 554.61 309.59 1.64 −0.15 −0.30 0.15
8b 1.09 365.46 594.35 340.35 2.07 −2.64 −1.75 −0.89
8c 1.03 353.34 575.63 322.77 1.39 −0.39 −0.53 0.14
8d 1.05 356.39 568.95 333.33 4.69 −2.72 −2.54 −0.18
8e 1.12 363.84 588.79 334.55 1.55 −0.72 −1.02 0.3
8f 0.97 356.88 581.58 322.42 0.36 −0.16 0.24 0.4
9d 1.11 491.05 756.77 345.12 4.60 −2.64 −2.79 0.15
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by the following abbreviations: s (singlet), d (doublet), 
dd (doublet of doublets), t (triplet), q (quartet), m (multi-
plet). Mass spectra were performed by direct infusion of 
target compounds. The data was recorded in ESI mode, 
either ES+ or ES−. TLC analyses were carried out on 
aluminium plates (Merck) coated with silica gel 60 F254 
(0.2 mm thickness). Visualization of spots was performed 
with UV light and by treatment with iodine. The MS and 
NMR data are available in the supplementary data (Addi-
tional files 1, 2 and 3).
General method for the preparation of compounds
General methods of synthesis for 7a–f
The synthesis followed the procedure described by Wang 
et al. [36] with some modification. A mixture containing 
equimolar quantities (8.6  mmol) of 4-(4-fluorobenzoyl)
piperidine hydrochloride, the substituted benzyl chloride 
in EtOH (15 mL) and NaOAc in distilled water (10 mL) 
was stirred and heated under reflux overnight. The mix-
ture was allowed to cool to room temperature and con-
centrated under reduced pressure to provide a residue. 
The residue was neutralized with a saturated solution 
of NaHCO3 (2  N, 50  mL) and extracted with CH2Cl2 
(2  ×  50  mL). The organic extracts were subsequently 
dried over anhydrous CaCl2, concentrated and set aside 
to give a residue. The product was purified using a short 
column of silica gel (hexane–ethyl acetate, 3:1). Reac-
tion conditions for compounds: compounds 7a–f were 
refluxed at 120 °C, while compounds 8a–f were refluxed 
at 60 °C and compounds 9d–f were refluxed at 120 °C.
4‑(4‑fluorobenzoyl)‑1‑[(4‑fluorophenyl)methyl]piperidine 
(7a)
Yield [from 4-(4-fluorobenzoyl)piperidine hydrochlo-
ride (2.0  g, 8.6  mmol), 4-fluorobenzyl chloride (1.2  g, 
8.6  mmol) and NaOAc (1.8  g, 8.6  mmol): sweet smell-
ing shiny cream solid (0.7  g, 51  %). m.p. 103–105  °C. 
1H NMR (CDCl3) δ 1.86 (br. s., 4H, H-3/H-5), 2.17 (br. 
s., 2H, Hax-2/Hax-6), 2.97 (d, 2H, J  =  11.2  Hz, Heq-2/
Heq-6), 3.22 (br. s., 1H, H-4), 3.54 (br. s., 2H, H-7″), 6.99 
(t, 2H, J  =  8.5  Hz, H-3′/H-5′), 7.13 (t, 2H, J  =  8.5  Hz, 
H-3″/H-5″), 7.31 (br. s., 2H, H-2″/H-6″), 7.95 (dd, 2H, 
J  =  8.2, 5.7  Hz, H-2′/H-6′). 13C NMR (CDCl3) δ 28.4 
(C-3/C-5), 43.9 (C-4), 52.7 (C-2/C-6), 62.2 (C-7″), 115.2 
(C-3′/C-5′), 115.9 (C-3″/C-5″), 130.7 (C-2″/C-6″), 130.8 
(C-2′/C-6′), 130.9 (C-1′), 132.4 (C-1″), 164.4 (C-4″), 
166.9 (C-4′), 201.0 (C-7′). [TOF MS ES+] calcd for 
C19H19F2NO m/z 315.14, found 338.16 (M + Na)+.
1‑[(3,4‑dichlorophenyl)methyl]‑4‑(4‑fluorobenzoyl)piperidine 
(7b)
Yield [from 4-(4-fluorobenzoyl)piperidine hydrochlo-
ride (2.0 g, 8.6 mmol), 3,4-dichlorobenzyl chloride (1.7 g, 
8.6  mmol) and NaOAc (1.8  g, 8.6  mmol): sweet smell-
ing shiny white solid (1.4 g, 44 %). m.p. 104–108  °C. 1H 
NMR (CDCl3) δ 1.77 (br. s., 4H, H-3/H-5), 2.07 (br. s., 
2H, Hax-2/Hax-6), 2.85 (d, 2H, J  =  11.3  Hz, Heq-2/Heq-
6), 3.14 (m, 1H, H-4), 3.41 (s, 2H, H-7″), 7.03–7.15 (m, 
3H, H-3′/H-5′, H-6″), 7.31 (d, 1H, J = 8.2 Hz, H-5″), 7.37 
(s, 1H, H-2″), 7.89 (dd, 2H, J =  8.4, 5.7  Hz, H-2′/H-6′). 
13C NMR (CDCl3) δ 28.6 (C-3/C-5), 43.5 (C-4), 53.0 
Fig. 4 Correlation plot for three‑descriptor QSAR relations a rela‑
tion 1, b relation 2 and c relation 3
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(C-2/C-6), 61.8 (C-7″), 115.9 (C-3′/C-5′), 128.1 (C-3″), 
130.2 (C-6″), 130.6 (C-5″), 130.8 (C-2′/C-2″), 130.9 (C-1′), 
132.3 (C-4″), 132.4 (C-1″), 166.9 (C-4′), 201.0 (C-7′).
1‑[(4‑chlorophenyl)methyl]‑4‑(4‑fluorobenzoyl)piperidine 
(7c)
Yield [from 4-(4-fluorobenzoyl)piperidine hydrochlo-
ride (2.0  g, 8.6  mmol), 4-chlorobenzyl chloride (1.4  g, 
8.6  mmol) and NaOAc (1.8  g, 8.6  mmol): sweet smell-
ing shiny white solid (1.4 g, 44 %). m.p. 115–117  °C. 1H 
NMR (CDCl3) δ 1.77 (m, 4H, H-3/H-5), 2.05 (br. s., 2H, 
Hax-2/Hax-6), 2.87 (d, 2H, J = 11.7 Hz, Heq-2/Heq-6), 3.13 
(m, 1H, H-4), 3.43 (s, 2H, H-7″), 7.06 (t, 2H, J = 8.4 Hz, 
H-3′/H-5′), 7.21 (m, 4H, H-2″/H-6″, H-3″/H-5″), 7.89 
(dd, 2H, J =  8.6, 5.5  Hz, H-2′/H-6′). 13C NMR (CDCl3) 
δ 28.7 (C-3/C-5), 43.6 (C-4), 53.0 (C-2/C-6), 62.4 (C-7″), 
115.9 (C-3′/C-5′), 128.4 (C-3″/C-5″), 130.3 (C-2′/C-6′), 
130.8 (C-1′), 130.9 (C-2″/C-6″), 132.5 (C-1″), 132.7 
(C-4″), 166.9 (C-4′), 201.0 (C-7′). [TOF MS ES+] calcd 
for C19H19ClFNO m/z 331.11, found 354.14 (M + Na)+.
Fig. 5 MEP maps for a spipethiane and the most potent σ1 ligand 7e, b spipethiane and the least potent σ1 ligand 8d and c the most potent 7e 
and its corresponding alcohol, 8e
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4‑(4‑fluorobenzoyl)‑1‑[(2‑nitrophenyl)methyl]piperidine (7d)
Yield [from 4-(4-fluorobenzoyl)piperidine hydrochlo-
ride (2.0  g, 8.6  mmol), 2-nitrobenzyl bromide (1.9  g, 
8.6 mmol) and NaOAc (1.8 g, 8.6 mmol): sweet smelling 
shiny brownish-yellow solid (1.3 g, 46 %). m.p. 95–97 °C. 
1H NMR (CDCl3) δ 1.80 (br. s., 4H, H-3/H-5), 2.19 (br. 
s., 2H, Hax-2/Hax-6), 2.87 (d, 2H, J  =  11.0  Hz, Heq-2/
Heq-6), 3.18 (m, 1H, H-4), 3.80 (s, 2H, H-7″), 7.11 (t, 2H, 
J =  8.6  Hz, H-3′/H-5′), 7.37 (t, 1H, J =  7.4  Hz, H-4″), 
7.53 (t, 1H, J = 7.4 Hz, H-5″), 7.68 (d, 1H, J = 7.4 Hz, 
H-6″), 7.82 (d, 1H, J  =  7.8  Hz, H-3″), 7.94 (dd, 2H, 
J  =  8.6, 5.5  Hz, H-2′/H-6′). 13C NMR (CDCl3) δ 28.7 
(C-3/C-5), 43.4 (C-4), 53.3 (C-2/C-6), 59.0 (C-7″), 115.9 
(C-3′/C-5′), 124.3 (C-3″), 127.7 (C-5″), 130.7 (C-6″), 
130.8 (C-1′), 130.9 (C-2′/C-6′), 132.4 (C-1″), 132.5 
(C-4″), 149.6 (C-2″), 166.9 (C-4′), 201.0 (C-7′). [TOF MS 




Yield [from 4-(4-fluorobenzoyl)piperidine hydro-
chloride (2.0  g, 8.6  mmol), 4-bromobenzyl chloride 
(1.2  g, 8.6  mmol) in EtOH (15  mL) and NaOAc (1.8  g, 
8.6  mmol): shiny white solid (0.8  g, 48  %). m.p. 125–
126  °C. 1H NMR (CDCl3) δ 1.77 (m, 4H, H-3/H-5), 
2.05 (br. s., 2H, Hax-2/Hax-6), 2.86 (d, 2H, J =  11.3  Hz, 
Heq-2/Heq-6), 3.13 (m, 1H, H-4), 3.41 (s, 2H, H-7″), 7.05 
(t, 2H, J =  8.6  Hz, H-3′/H-5′), 7.14 (d, 2H, J =  8.2  Hz, 
H-3″/H-5″), 7.36 (d, 2H, J  =  8.2  Hz, H-2″/H-6″), 7.88 
(dd, 2H, J =  8.4, 5.7 Hz, H-2′/H-6′). 13C NMR (CDCl3) 
δ 28.7 (C-3/C-5), 43.5 (C-4), 53.0 (C-2/C-6), 62.4 (C-7″), 
115.8 (C-3′/C-5′), 120.8 (C-4″), 130.6 (C-2′/C-6′), 
130.9 (C-2″/C-6″), 131.3 (C-3″/C-5″), 132.4 (C-1′), 
137.4 (C-1″), 166.9 (C-4′), 201.0 (C-7′). [TOF MS ES+] 





ride (2.0  g, 8.6  mmol), 4- methylbenzyl chloride(1.7  g, 
8.6  mmol) and NaOAc (1.8  g, 8.6  mmol): sweet smell-
ing colorless shiny solid (0.7 g, 46 %). m.p. 108–110  °C. 
1H NMR (CDCl3) δ 1.82 (m, 4H, H-3/H-5), 2.09 (td., 2H, 
J = 10.8, 3.5 Hz, Hax-2/Hax-6), 2.32 (s, 3H, 4″-CH3), 2.95 
(d, 2H, J = 11.7 Hz, Heq-2/Heq-6), 3.17 (m, 1H, H-4), 3.50 
(s, 2H, H-7′), 7.11 (m, 4H, H-3′/H-5′, H-3″/H-5″), 7.20 (d, 
2H, J = 7.3 Hz, H-2″/H-6″), 7.94 (dd, 2H, J = 8.4, 5.7 Hz, 
H-2′/H-6′). 13C NMR (CDCl3) δ 21.1 (4″-CH3), 28.7 
(C-3/C-5), 43.7 (C-4), 53.0 (C-2/C-6), 62.9 (C-7″), 115.8 
(C-3′/C-5′), 128.9 (C-3″/C-5″), 129.1 (C-2″/C-6″), 130.9 
(C-2′/C-6′), 132.5 (C-1′), 135.1 (C-1″), 136.6 (C-4″), 166.8 
(C-4′), 201.1 (C-7′). [TOF MS ES+] calcd for C20H22FNO 
m/z 311.17, found 334.16 (M + Na)+.
General method for the preparation of compounds 8a–f
The synthesis followed the procedure described by Mach 
et al. [33] with some modification.
Added to a suspension each of 7a–f in THF (10  mL) 
was four equivalents of hydrogen from LiBH4 all in 
equimolar quantities in THF (10  mL). The mixture was 
stirred for 30 min, heated at reflux overnight and allowed 
to cool to room temperature. The mixture was then con-
centrated to remove the THF and then treated with dis-
tilled water. The organic phase extracted with CH2Cl2 
(2  ×  20  mL), washed with brine, dried over CaCl2 and 
evaporated to dryness. The product crystallized sponta-
neously, was washed with hexane, filtered and air dried.
(4‑fluorophenyl)({1‑[(4‑fluorophenyl)methyl]piperidin‑4‑yl})
methanol (8a)
Yield [from 7a (0.4  g, 1.2  mmol), LiBH4 (0.03  g, 
1.2 mmol). Solid (0.4 g, 97 %). m.p. 133–134 °C. 1H NMR 
(CD3OD) δ 1.14 (m, 2H, Hax-3/Hax-5), 1.29 (m, 2H, Heq-3/
Heq-5), 1.46 (m, 1H, H-4), 1.81 (m, 2H, Hax-2/Hax-6), 2.71 
(d, 1H, J = 11.3 Hz, Heq-2), 2.82 (d, 1H, J = 11.3 Hz Heq-
6), 3.35 (s, 2H, H-7″), 4.20 (d, 1H, J = 7.8 Hz, H-7′), 6.93 
(m, 4H, H-3′/H-5′, H-3″/H-5″), 7.20 (m, 4H, H-2′/H-6′, 
H-2″/H-6″). 13C NMR (CDCl3) δ 27.7 (C-3), 27.9 (C-5), 
43.0 (C-4), 52.9 (C-2), 53.0 (C-6), 61.9 (C-7″), 77.2 (C-7′), 
114.3 (C-3″/C-5″), 114.5 (C-3′/C-5′), 128.1 (C-2″/C-6″), 
131.1 (C-2′/C-6′), 133.0 (C-1″), 139.5 (C-1′), 160.9 (C-4″), 
163.4 (C-4′). [TOF MS ES+] calcd for C19H21F2NO m/z 
317.16, found 318.18 (M + H)+.
{1‑[(3,4‑dichlorophenyl)methyl]piperidin‑4‑yl}
(4‑fluorophenyl)methanol (8b)
Yield [from 7b (0.4  g, 1.0  mmol), LiBH4 (0.02  g, 
1.0  mmol). Solid (0.4  g, 99  %). m.p. 84–86  °C.1H NMR 
(CD3OD) δ 1.14 (m, 2H, Hax-3/Hax-5), 1.27 (m, 2H, Heq-3/
Fig. 6 Superposition of spipethiane (cyan), the most potent (purple) 
and least potent (green) σ1 receptor ligands
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Heq-5), 1.46 (m, 1H, H-4), 1.83 (m, 2H, Hax-2/Hax-6), 2.69 
(d, 1H, J = 11.3 Hz, Heq-2), 2.80 (d, 1H, J = 11.3 Hz Heq-
6), 3.34 (s, 2H, H-7″), 4.21 (d, 1H, J = 7.4 Hz, H-7′), 6.93 
(t, 2H, J =  8.6  Hz, H-3′/H-5′), 7.12 (d, 1H, J =  8.2  Hz, 
H-6″), 7.20 (dd, 2H, H-2′/H-6′), 7.34 (d, 1H, J = 8.2 Hz, 
H-5″), 7.38 (s, 1H, H-2″). 13C NMR (CDCl3) δ 29.5 (C-3), 
29.6 (C-5), 44.6 (C-4), 54.6 (C-2), 54.8 (C-6), 62.9 (C-7″), 
78.8 (C-7′), 115.9 (C-3′/C-5′), 129.7 (C-2′/C-6′), 130.5 
(C-3″), 131.5 (C-6″), 132.2 (C-5″), 132.6 (C-2″), 133.3 
(C-4″), 140.1 (C-1″), 141.1 (C-1′), 164.8 (C-4′). [TOF MS 




Yield [from 7c (0.40  g, 1.1  mmol), LiBH4 (0.02  g, 
1.1  mmol): Solid (0.4  g, 99  %). m.p. 113–116  °C. 1H 
NMR (CD3OD) δ 1.15 (m, 2H, Hax-3/Hax-5), 1.28 (m, 
Fig. 7 Molecular surfaces map for a spipethiane and most potent σ1 ligand, b spipethiane and least potent σ1 ligand and c most potent and least 
potent σ1 ligands
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2H, Heq-3/Heq-5), 1.47 (m, 1H, H-4), 1.84 (m, 2H, 
Hax-2/Hax-6), 2.72 (d, 1H, J = 11.3 Hz, Heq-2), 2.83 (d, 
1H, J = 11.3 Hz, Heq-6), 3.37 (s, 2H, H-7″), 4.21 (d, 1H, 
J  =  7.4  Hz, H-7′), 6.93 (t, 2H, J  =  8.6  Hz H-3′/H-5′), 
7.20 (m, 6H, H-2′/H-6′, H-2″/H-6″, H-3″/H-5″). 13C 
NMR (CDCl3) δ 29.3 (C-3), 29.5 (C-5), 44.5 (C-4), 
54.6 (C-2), 54.7 (C-6), 63.4 (C-7″), 78.7 (C-7′), 115.8 
(C-3′/C-5′), 129.5 (C-3″/C-5″), 129.8 (C-2′/C-6′), 132.5 




Yield [from 7d (0.5  g, 2.0  mmol), LiBH4 (0.03  g, 
2.0 mmol): yellow oil (0.5 g, 98 %). was obtained, washed 
with hexane and air dried. 1H NMR (CD3OD) δ 1.08 (m, 
2H, Hax-3/Hax-5), 1.21 (m, 2H, Heq-3/Heq-5), 1.40 (m, 1H, 
H-4), 1.83 (m, 2H, Hax-2/Hax-6), 2.59 (d, 1H, J = 11.0 Hz, 
Heq-2), 2.70 (d, 1H, J = 11.0 Hz, Heq-6), 3.60 (s, 2H, H-7″), 
4.16 (d, 1H, J  =  7.8  Hz, H-7′), 6.92 (t, 2H, J  =  8.8  Hz 
H-3′/H-5′), 7.18 (dd, 2H, J = 8.0, 5.7 Hz, H-2′/H-6′), 7.33 
(dt, 1H, J =  8.3, 4.3  Hz, H-4″), 7.46 (d, 2H, J =  4.3  Hz, 
H-5″/H-6″), 7.68 (d, 1H, J  =  7.8  Hz, H-3″). 13C NMR 
(CDCl3) δ 29.8 (C-3), 29.9 (C-5), 44.7 (C-4), 54.9 (C-2), 
55.0 (C-6), 60.3 (C-7″), 78.9 (C-7′), 116.0 (C-3′/C-5′), 
125.4 (C-3″), 129.4 (C-5″), 129.7 (C-2′/C-6′), 132.7 (C-6″), 




Yield [from 7e (0.5  g, 1.3  mmol), LiBH4 (0.03  g, 
1.3  mmol): solid (0.4  g, 95  %). m.p. 75–78  °C. 1H NMR 
(CD3OD) δ 1.14 (m, 2H, Hax-3/Hax-5), 1.26 (m, 2H, Heq-3/
Heq-5), 1.46 (m, 1H, H-4), 1.82 (m, 2H, Hax-2/Hax-6), 2.71 
(d, 1H, J = 11.3 Hz, Heq-2), 2.82 (d, 1H, J = 11.3 Hz, Heq-
6), 3.34 (s, 2H, H-7″), 4.20 (d, 1H, J = 7.8 Hz, H-7′), 6.93 
(t, 2H, J =  8.8  Hz, H-3′/H-5′), 7.12 (d, 2H, J =  8.2  Hz, 
H-2″/H-6″), 7.19 (dd, 2H, J  =  8.2, 5.5  Hz, H-2′/H-6′), 
7.35 (d, J = 8.2 Hz, H-3″/H-5″). 13C NMR (CDCl3) δ 29.3 
(C-3), 29.5 (C-5), 44.5 (C-4), 54.6 (C-2), 54.7 (C-6), 63.5 
(C-7″), 78.8 (C-7′), 116.0 (C-3′/C-5′), 122.3 (C-4″), 129.8 
(C-2′/C-6′), 132.5 (C-2″/C-6″), 132.8 (C-3″/C-5″), 138.0 
(C-1″), 141.1(C-1′), 164.8 (C-4′). [TOF MS ES+] calcd for 
C19H21BrFNO m/z 377.08, found 378.11 (M + H)+.
(4‑fluorophenyl)({1‑[(4‑methylphenyl)methyl]piperidin‑4‑yl})
methanol (8f)
Yield [from 7f (0.4 g, 1.2 mmol), LiBH4 (0.02 g, 1.2 mmol). 
Solid (0.4  g, 98  %). m.p. 94–95  °C. 1H NMR (CD3OD) 
δ 1.13 (m, 2H, Hax-3/Hax-5), 1.27 (m, 2H, Heq-3/Heq-5), 
1.45 (m, 1H, H-4), 1.80 (m, 2H, Hax-2/Hax-6), 2.20 (s, 
3H, 4″-CH3), 2.72 (d, 1H, J  =  11.3  Hz, Heq-2), 2.83 (d, 
1H, J = 11.3 Hz, Heq-6), 3.33 (s, 2H, H-7″), 4.19 (d, 1H, 
J = 7.4 Hz, H-7′), 6.93 (t, 2H, J = 8.6 Hz, H-3′/H-5′), 7.01 
(d, 2H, J = 7.8 Hz, H-3″/H-5″), 7.06 (d, 2H, J = 7.8 Hz, 
H-2″/H-6″), 7.19 (dd, J  =  8.2, 5.5  Hz, H-2′/H-6′). 13C 
NMR (CDCl3) δ 21.3 (4″-CH3), 29.2 (C-3), 29.4 (C-5), 
44.6 (C-4), 54.5 (C-2), 54.6 (C-6), 64.1 (C-7″), 78.8 (C-7′), 
116.0 (C-3′/C-5′), 129.8 (C-2′/C-6′), 130.0 (C-2″/C-6″), 
131.0 (C-3″/C-5″), 135.1 (C-1″), 138.3 (C-4″), 141.1(C-1′), 
164.8 (C-4′). [TOF MS ES+] calcd for C20H24FNO m/z 
313.18, found 314.19 (M + H)+.
General method for the preparation of compounds 9d–e
The synthesis followed the procedure described by 
Abdel-Magid et  al. [34] with some modification. Equi-
molar quantities of each 7d–e and 3-bromobenzylamine 
Fig. 8 Pharmacophore generation from most potent and least potent σ1 ligands
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hydrochloride were weighed in a round bottom flask. 
Added into the flask was THF (15 mL), equimolar quan-
tity of LiBH4 and acetic acid (2  mL). The mixture was 
stirred and heated under reflux for 3  days and allowed 
to cool to room temperature. The mixture was then 
concentrated to remove the THF and then washed with 
NaHCO3 (2 N, 30 mL). The organic phase extracted with 
CH2Cl2 (2  ×  30  mL) and dried over CaCl2 and evapo-
rated to dryness. The product crystallized spontaneously, 
was washed with hexane, filtered and air dried.
[(3‑bromophenyl)methyl][(4‑fluorophenyl)
({1‑[(2‑nitrophenyl)methyl]piperidin‑4‑yl})methyl]amine (9d)
Yield [from 7d (0.4  g, 1.0  mmol), 3-bromobenzylamine 
hydrochloride (0.2  g, 1.0  mmol), LiBH4 (0.02  g, 
1.0  mmol), AcOH (2  mL), THF (15  mL). Yellow oil 
(0.4 g, 48 %) was obtained, washed with hexane and air 
dried. 1H NMR (CD3OD) δ 1.15 (m, 2H, Hax-3/Hax-5), 
1.31 (m, 2H, Heq-3/Heq-5), 1.49 (m, 1H, H-4), 1.92 (m, 
2H, Hax-2/Hax-6), 2.68 (d, 1H, J =  11.0  Hz, Heq-2), 2.79 
(d, 1H, J =  11.0  Hz, Heq-6), 3.69 (s, 2H, H-7″), 4.24 (d, 
1H, J  =  7.4  Hz, H-7′), 4.31 (s, 1H, Ha-7‴), 4.76 (s, 1H, 
Hb-7‴), 7.01 (t, 2H, J  =  8.8  Hz, H-3′/H-5′), 7.19-7.44 
(m, 7H, H-2′/H-6′, H-4″, H-5″, H-6″, H-5‴, H-6‴), 7.54 
(m, 2H, H-3″, H-2‴), 7.77 (d, 1H, J = 8.2 Hz, H-4‴). 13C 
NMR (CDCl3) δ 29.9 (C-3/C-5), 44.7 (C-4), 54.9 (C-2), 
55.0 (C-6), 60.3 (C-7″), 65.0 (C-7‴), 78.9 (C-7′), 116.0 
(C-3′/C-5′), 125.4 (C-3″), 127.5 (C-3‴), 128.0 (C-6‴), 
128.5 (C-5‴), 129.4 (C-5″), 129.7 (C-2′/C-6′), 131.4 
(C-4‴), 132.2 (C-2‴), 132.7 (C-6″), 133.5 (C-1″), 134.8 




Yield [from 7e (0.4  g, 1.1  mmol), 3-bromobenzylamine 
hydrochloride (0.3  g, 1.1  mmol), LiBH4 (0.02  g, 
1.1 mmol), AcOH (2 mL), THF (15 mL). Yellow oil (0.3 g, 
42  %) was obtained, washed with hexane and air dried. 
1H NMR (CD3OD) δ 1.13 (m, 2H, Hax-3/Hax-5), 1.28 (m, 
2H, Heq-3/Heq-5), 1.47 (m, 1H, H-4), 1.86 (m, 2H, Hax-2/
Hax-6), 3.10 (d, 1H, J  =  12.1  Hz, Heq-2), 3.18 (d, 1H, 
J =  12.1  Hz, Heq-6), 3.87 (s, 2H, H-7″), 4.09 (s, 1H, Ha 
-7‴), 4.24 (m, 2H, H-7′, Hb -7‴), 6.96 (t, 2H, J = 8.8 Hz, 
H-3′/H-5′), 7.12 (d, 1H, J = 6.7 Hz, H-6‴), 7.21-7.32 (m, 
6H, H-2′/H-6′, H-2″/H-6″, H-3″/H-5″), 7.34 (m, 1H, 
H-5‴), 7.49 (m, 2H, H-2‴, H-4‴). 13C NMR (CDCl3) δ 
27.5 (C-3), 27.8 (C-5), 43.7 (C-4), 52.1 (C-7‴), 53.6 (C-2), 
53.8 (C-6), 61.5 (C-7″), 77.7 (C-7′), 116.1 (C-3′/C-5′), 
124.4 (C-4″), 127.5 (C-3‴), 128.0 (C-6‴), 128.5 (C-5‴), 
129.8 (C-2′/C-6′), 131.7 (C-4‴), 132,1 (C-2‴), 133.1 
(C-2″/C-6″), 133.7 (C-1‴), 133.8 (C-3″/C-5″), 134.0 
(C-1″), 143.8 (C-1′), 164.9 (C-4′).
Sigma receptor binding
These experiments were performed as described by Jin-
bin et  al. [48] with some modification. Different con-
centrations of test samples were achieved by diluting 
stock solutions with a solution containing 50 mM Tris–
HCl, 150  mM NaCl and 100  mM EDTA at pH 7.4. Rat 
liver membrane homogenates (~300  μg protein) were 
diluted with 50  mM Tris–HCl buffer, pH 8.0 and incu-
bated in a total volume of 150 μL with the radioligand at 
25 °C in 96 well plates. The incubation time was 60 min 
for test compounds and 120 min for [3H] DTG and [3H] 
(+)-pentazocine.
For determination of sigma 1 binding affinities, the 
σ2 sites were masked in the presence of 1 μM [3H]DTG 
to determine the σ1 receptor binding characteristics of 
[3H] (+)-pentazocine while the σ1 sites were masked 
in the presence of 1  μM (+)-pentazocine to determine 
the σ2 receptor binding characteristics of [3H]DTG. It 
is worth mentioning that, this was done one at a time. 
The final concentration of the radioligand in each assay 
was ~1 nM for [3H] test compounds and ~5 nM for [3H] 
(+)-pentazocine and [3H]DTG. Nonspecific binding was 
determined from samples that contained 10 μM of cold 
haloperidol.
The reaction was started by adding 0.2 mL of the mem-
brane preparation to the 50 mM Tris–HCl (pH 8.0) buffer 
containing 3H-labeled ligand with a final concentration of 
5 nM and cold ligand ranging from 0.01 to 0.1 mM in a 
final volume of 1.0 mL. Incubations were carried out at 
37 °C for 150 min in the binding study with [3H] (+)-pen-
tazocine and at 25  °C for 90 min in the study with [3H] 
DTG. Inhibitor concentrations ranging from 0.1  nM to 
10 μM were added to acquire the inhibition curves. After 
the reaction was completed, the samples were harvested, 
washed three times, and the bound radioactivity counted 
and analyzed. Data from the competitive inhibition 
experiments were modeled using nonlinear regression 
analysis to determine the concentration of inhibitor that 
inhibits 50  % of the specific binding of the radioligand 
(IC50 value) and the competitive inhibition constants (Ki 
values) were calculated from the IC50.
Computational methodology
All molecular modeling was carried out using the soft-
ware, MOE [49]. Initially, each compound was sketched 
using the Builder module of MOE package. Energy 
minimization was carried out using the MOPAC mod-
ule of MOE at the AM1 level of theory using a minimi-
zation gradient of 0.001  kcal/mol. For compounds with 
chiral centres, only the R-isomers were considered. In 
the generation of MEPs, the cut-offs were set at 1.62  Å. 
Pharmacophore models were generated using the polar-
ity-charge-hydrophobicity (PCH) scheme implemented in 
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MOE. The binding sites were defined by mapping the top-
ographical arrangement of the phenyl rings, N-atoms and 
the electronegative atoms as described by Gund et al. [13].
The binding affinities to the σ1 receptor were computed 
using Eq. 4:
where R is the ideal gas constant and T is the absolute 
temperature. The residual binding affinities were com-
puted as:
These values give a measure of the error estimates for 
individual values calculated by the regression equation 
for the dataset. Similarly, the residual values for experi-
mental and predicted activities were obtained from the 
difference between pICexp50  and pIC
pred
50 . This value gives 
a measure of the error in estimates for individual values 
calculated by the regression equation for the data set.
Conclusions
The replacement of spirofusion in the lead compound 1 
by either a hydroxymethylene or carbonyl bridge led to 
4-aroylpiperidines and 4-(α-hydroxyphenyl)piperidines. 
Most of the compounds have high affinity for σ1 recep-
tors and fit well into the Gund’s pharmacophore model 
for σ1 receptor ligands; they also display poor affinity 
for σ2 receptors, and finally, some of them have a higher 
selectivity for the σ1 receptor compared to the lead com-
pound 1. Thus, spirofusion confers no particular advan-
tage in 1 over its ring open analogues. These analogues 
with secondary binding sites like H-bond acceptors as 
well as H-bond donors both emerged as potent σ1 recep-
tor ligands. Therefore, the secondary binding site pro-
posed by Lu et al. [7], may either be a H-bond donor or 
acceptor. Following the ph4 models generated in this 
study, potential σ1 binders could be virtually screened 
from our recently developed natural product libraries 
from African medicinal plants [50–53].
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